Navigation Links
Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
Date:5/25/2010

aken by patients who have advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; known hypersensitivity or idiosyncrasy to sympathomimetic amines; agitated states; glaucoma; a history of drug abuse; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs).

Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.  Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses in ADHD.  Physicians should take a careful patient history, including family history, and physical exam, to assess the presence of cardiac disease.  Patients who report symptoms of cardiac disease such as exertional chest pain and unexplained syncope should be promptly evaluated.  Use with caution in patients whose underlying medical condition might be affected by increases in blood pressure or heart rate.

New psychosis, mania, aggression, growth suppression, visual disturbances and exacerbation of tics and Tourette's syndrome have been associated with the use of stimulants.  Use with caution in patients with a history of psychosis, seizures or EEG abnormalities, bipolar disorder, or depression.  Growth should be monitored in children during treatment with stimulants, and patients who are not growing (gaining height or weight) as expected may need to have their treatment interrupted.

The most common adverse reactions (greater than or equal to 5 percent and at least twice the rate of placebo) reported in the pivotal clinical trials were pediatric – decreased appetite, insomnia, upper abdominal pain, irritability, decreased weight, vomiting, nausea, dizziness and dry mouth; adult
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 Cambridge Semantics , ... by Semantic Web technology, and Informa , ... services for the academic and scientific, professional and ... solution ‘Smart Data Lake for Clinical Trial and ... 2015 Bio-IT ‘Best of Show’ Award. , ...
(Date:4/16/2015)... April 16, 2015 Regis Technologies looks ... Association for Cancer Research (AACR) annual meeting. Regis will ... Center, starting Saturday, April 18, in Philadelphia and running ... to title of the oldest and largest organization focused ... and grants, and partners with survivors to promote awareness ...
(Date:4/16/2015)... , April 16, 2015 /PRNewswire/ - Portage Biotech Inc. ... Securities Exchange: PBT.U), is pleased to announce that the ... on April 25, 2015 to be held in ... Gregory Bailey and Mr. James Mellon , ... an update on the key programs at its subsidiaries, ...
(Date:4/16/2015)... DIEGO , April 16, 2015  AnaptysBio, ... development of therapeutic antibodies, today announced the ... antibody program into IND-enabling studies. The Company,s ... novel treatment for generalized pustular psoriasis (GPP), ... unmet medical need. ANB019 is wholly owned within ...
Breaking Biology Technology:Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... Other important parameters for optimizing electroporation., , , , , , , ... , Pulse length , , ... Adjustment , of the electroporation buffer , ... Influence , of temperature , Influence ...
... , , , , ... , to degradation than DNA. Unlike Deoxyribonucleases (DNases), ... can therefore easily be inactivated with chelating , ... requirements and advantage of the 2 hydroxyl groups adjacent to ...
... How can Brinkmann TM Help ? , , , , , ... , , ... laboratory technique that is performed everyday, for a good portion , ... Due to the nature of the tests being conducted, only short breaks , ...
Cached Biology Technology:Optimizing electroporation parameters 2Optimizing electroporation parameters 3Optimizing electroporation parameters 4Optimizing electroporation parameters 5Decontamination and inhibition of ribonucleases 2Decontamination and inhibition of ribonucleases 3Decontamination and inhibition of ribonucleases 4Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 2Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 3Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 4
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... are significantly more open to the idea of "designing" babies ... psychologists at the University of East Anglia. , The findings ... Festival of Science on Setpember 5. , Dr. Hampton and ... Studies examined what different groups of people in the UK ...
... that influences several aspects of nicotine-induced behaviors in the ... Drug Abuse, was presented today at the American College ... PhD, associate professor of psychiatry and her colleagues at ... a molecule called CREB in a brain area called ...
... In a finding that broadens our understanding of ... risk when crossing roads and draw on an ... primates--of protective "socio-spatial" organization that produces flexible, adaptive, ... facing risk. The research is reported by Kimberley ...
Cached Biology News:Designer babies - what would you do for a 'healthy' baby? 2New research identifies gene important for nicotine's effects on the brain 2Road-crossing in chimpanzees: A risky business 2
Performance, mycoplasma, virus, and endotoxin tested...
... Gel Loading Buffer is ... and tracking of DNA ... native polyacrylamide gels. This ... density sucrose which allows ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
ready-to-use solution...
Biology Products: